Kallikrein 5/KLK5 Protein, Mouse, Recombinant (His)

The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.

规格	价格/CNY		数量
100 μg	￥ 2,660	5日内发货
500 μg	￥ 10,600	5日内发货
1 mg	￥ 17,800	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 2,660

5日内发货

500 μg

￥ 10,600

5日内发货

1 mg

￥ 17,800

5日内发货

产品描述

种属	Mouse
表达系统	HEK293
标签	C-His
蛋白编号	Q9D140
别名	SCTE, KLKL2, KLK5, KLK-L2, Klnc, Kallikrein c
蛋白构建	Recombinant Mouse Kallikrein 5/KLK5 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Gly30-Asn293.[Accession \|Q9D140]
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
分子量	The protein has a predicted MW of 29.9 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.

内毒素	Less than 1EU per μg by the LAL method.
缓冲液	Lyophilized from 0.22μm filtered solution in 20mM NaAc, 150mM NaCl (pH 5.0). Normally 8% trehalose is added as protectant before lyophilization.
复溶方法	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM NaAc, 150mM NaCl (pH 5.0).
存储	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
运输方式	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
研究背景	The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.